Effects of Immunotherapy
21
7
7
10
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 21 trials
100.0%
+13.5% vs benchmark
10%
2 trials in Phase 3/4
10%
1 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (21)
A Study of TIL in Advanced Solid Tumors (DFGD)
A Study of GC101 TIL in Advanced Breast Cancer (10hospital)
A Study of GC101 TIL in Advanced Melanoma (10hospital)
A Study of GC203 TIL in Advanced Gynecologic Tumors (10hospital)
A Study of GC201 TIL in Advanced Gynecologic Tumors (10hospital)
A Study of GC101 TIL in Advanced Hepatobiliary-Pancreatic Cancers (10hospital)
Safety Study of a Dendritic Cell-based Cancer Vaccine in Melanoma
Impact of Gonadotoxic Therapies on Fertility
Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer
Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma
A Clinical Study on TIL for the Treatment of Advanced Solid Tumors
Anti-GD2 4th Generation CART Cells Targeting Refractory and/or Recurrent Neuroblastoma
TIL and Anti-PD1 in Metastatic Melanoma
Serum MicroRNAs 223 and 146a in Allergic Rhinitis Patients as Biomarkers for Efficacy of Sublingual Immunotherapy
Real-world Study of Efficacy and Safety of ICIs and TKIs Therapy for HCC
Effect of Sublingual Immunotherapy in Patients With Atopic Dermatitis
Trial of SBRT With Concurrent Ipilimumab in Metastatic Melanoma
SCH708980 With and Without AmBisome for Visceral Leishmaniasis
Safety and Immunogenicity of Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic Combined With Infusion of Treg Depleted T Cells for Adult WT1 Acute Myeloid Leukemia
Quality of Life and Health Economic Measurements in Allergic Patients Treated With Immunotherapy